ETGLX - Eventide Gilead N

Nasdaq - Nasdaq Delayed Price. Currency in USD
+0.24 (+0.66%)
As of 8:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close36.16
YTD Return3.15%
Expense Ratio (net)1.40%
CategoryMid-Cap Growth
Morningstar Rating★★★★☆
Morningstar Risk RatingHigh
Last Cap Gain0.00
Net Assets1.65B
Beta (3y)1.27
Holdings Turnover26.00%
Last Dividend0.00
Inception DateJul 1, 2008
Average for CategoryN/A
  • PR Newswire2 months ago

    Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund Named WSJ Category Kings for 2017

    BOSTON, Jan. 30, 2018 /PRNewswire/ -- The Eventide Gilead Fund (ETILX) and the Eventide Healthcare & Life Sciences Fund (ETIHX) were both named as "Category Kings" by the Wall Street Journal for 2017. Both Funds are managed by Eventide Asset Management, LLC, a Boston-based registered investment adviser that designs investments for performance and a better world. Eventide CEO Robin John commented, "We are pleased with the results, yet more importantly, proud of how they were achieved.

  • PR Newswire8 months ago

    Eventide Gilead Fund Named a WSJ Category King

    BOSTON, July 31, 2017 /PRNewswire/ -- The Eventide Gilead Fund (NASDAQ: ETGLX, NASDAQ: ETAGX, NASDAQ: ETCGX, NASDAQ: ETILX) received a Wall Street Journal "Category King" on June 30, 2017. The award recognizes the top 10 funds in each equity category for one-year total return performance.

  • We're sorry this is all we were able to find about this topic.